Company Encyclopedia
View More
name
Harmony Biosciences
HRMY.US
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 1 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and High-Dose (HD). In addition, the company’s products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist.
4.514 T
HRMY.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking19/183
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE25.93%A
    • Profit Margin22.48%A
    • Gross Margin75.09%A
  • Growth ScoreA
    • Revenue YoY21.13%A
    • Net Profit YoY51.42%B
    • Total Assets YoY30.18%A
    • Net Assets YoY39.93%A
  • Cash ScoreB
    • Cash Flow Margin444.83%C
    • OCF YoY21.13%A
  • Operating ScoreB
    • Turnover0.77B
  • Debt ScoreB
    • Gearing Ratio30.88%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    A Look at Harmony Biosciences (HRMY) Valuation Following Key Pipeline Advancements and Positive Trial Results

    Harmony Biosciences Holdings (HRMY) reported positive results from a pivotal bioequivalence study and started a Phase 1 trial for a new orexin 2 receptor agonist. These updates have driven a 24.3% share price increase over the past month. Despite short-term gains, long-term returns remain modest. Analysts set a price target nearly 30% above current levels, suggesting the stock is undervalued. Strategic capital allocation and robust cash generation support R&D and pipeline expansion without near-term dilution risk. Future setbacks or increased competition could challenge growth outlook.

    Simplywall·
    US
    HRMY
    +3.38%
    Simplywall·
    US
    HRMY
    +3.38%

    Harmony Biosciences Unveils New Phase 3 ARGUS Trial Data on EPX-100 for Dravet Syndrome

    Harmony Biosciences Holdings Inc. announced new data from its Phase 3 ARGUS trial on EPX-100 for Dravet syndrome, to be presented at the 2025 American Epilepsy Society Annual Meeting in Atlanta. The trial is currently enrolling participants, and presentations will include preliminary results and a drug-drug interaction study. This information was originally published by Harmony Biosciences via Business Wire.

    Reuters·
    US
    HRMY
    +3.38%
    Reuters·
    US
    HRMY
    +3.38%

    Harmony Biosciences CFO Sandip Kapadia Reports Sale of Common Shares

    Sandip Kapadia, CFO of Harmony Biosciences Holdings Inc., reported the sale of common shares of the company. The full filing is available via EDGAR, the U.S. SEC's system.

    Reuters·
    US
    HRMY
    +3.38%
    Reuters·
    US
    HRMY
    +3.38%

    237,726 Shares in Harmony Biosciences Holdings, Inc. $HRMY Acquired by Tieton Capital Management LLC

    Tieton Capital Management LLC acquired 237,726 shares of Harmony Biosciences, valued at $7.5 million, making it 3.1% of their holdings. Analysts have mixed ratings, with a Moderate Buy consensus and an average price target of $44.63. Harmony Biosciences reported Q3 earnings of $0.87 per share, missing estimates, with revenue of $239.46 million. The stock opened at $34.31, with a market cap of $1.98 billion.

    Market Beat·
    US
    HRMY
    +3.38%
    Market Beat·
    US
    HRMY
    +3.38%

    Harmony Biosciences (HRMY): Valuation in Focus After First Patient Dosed in New Narcolepsy Drug Trial

    Harmony Biosciences (HRMY) has initiated its Phase 1 clinical trial for BP1.15205, targeting narcolepsy. This milestone follows promising preclinical results. Despite recent stock momentum, long-term returns remain negative. The stock is considered undervalued at $35.27, with a fair value of $44.55. Investors are evaluating growth prospects amid competitive and regulatory challenges. Harmony's diversified pipeline and strategic management are seen as strengths. The analysis highlights potential rewards and risks for investors.

    Simplywall·
    US
    HRMY
    +3.38%
    Simplywall·
    US
    HRMY
    +3.38%
    © 2025 Longbridge｜Disclaimer